Cocrystal Pharma Inc (COCP)

[someconcerns]

New SEC fling: https://biz.yahoo.com/e/160613/cocp8-k.html


Item 7.01 Regulation FD Disclosure

While attending the Jefferies 2016 Healthcare Conference held in New York City from June 7-10, 2016, Dr. Douglas Mayers, Chief Medical Officer of Cocrystal Pharma, Inc. (the "Company") disclosed in private comments that the Company intends to pursue uplisting to the Nasdaq Stock Market in the coming year, in conjunction with which the Company would likely engage in capital-raising efforts. The Company is not presently engaged in an offering of the Company's securities and does not presently have any specific plans to raise capital. The Company cannot offer any assurances as to when, or if, the Company will apply to Nasdaq, and if the Company does apply to Nasdaq, it cannot offer any assurances as to whether the Company's securities will be accepted for listing.

The information in Item 7.01 of this report is furnished pursuant to Item 7.01 of Form 8-K and shall not be deemed "filed" for the purposes of Section 18 of the Securities Exchange Act of 1934 or otherwise subject to the liabilities of that section. Furthermore, the information in Item 7.01 of this report shall not be deemed to be incorporated by reference in the filings of the registrant under the Securities Act of 1933.